Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial

Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation

(2021) Jing-Rui Zhou et al.   Frontiers in Immunology

Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes

(2020) Yuhua Ru et al.   BONE MARROW TRANSPLANTATION

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

(2020) Irwin Walker et al.   Lancet Haematology

Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study

(2020) Ying-Jun Chang et al.   JOURNAL OF CLINICAL ONCOLOGY

GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study

(2019) Francesca Bonifazi et al.   Lancet Haematology

Early Cytomegalovirus Reactivation and Expansion of CD56brightCD16dim/−DNAM1+ Natural Killer Cells Are Associated with Antileukemia Effect after Haploidentical Stem Cell Transplantation in Acute Leukemia

(2019) Ji Eun Jang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study

(2019) Ren Lin et al.   BMC Medicine

EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

(2018) Helene M. Schoemans et al.   BONE MARROW TRANSPLANTATION

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

(2018) Lanping Xu et al.   Journal of Hematology & Oncology

The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China

(2018) Yu Wang et al.   CANCER LETTERS

The role of collateral related donors in haploidentical hematopoietic stem cell transplantation

(2018) Xiao-Dong Mo et al.   Science Bulletin

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

(2017) Robert J. Soiffer et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial

(2017) Franco Locatelli et al.   LANCET ONCOLOGY

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial

(2017) Jürgen Finke et al.   Lancet Haematology

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

(2016) Irwin Walker et al.   LANCET ONCOLOGY

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

(2016) Nicolaus Kröger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

(2015) S. G. Holtan et al.   BLOOD

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

(2014) P. Armand et al.   BLOOD

Nonmalignant Late Effects in Survivors of Partially Matched Donor Hematopoietic Stem Cell Transplantation

(2013) Xiao-Dong Mo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial

(2013) Y Wang et al.   BONE MARROW TRANSPLANTATION

Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse

(2012) M Hoegh-Petersen et al.   BONE MARROW TRANSPLANTATION

Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation

(2011) Nandita Khera et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY